Frontline Asciminib Combination in Chronic Phase CML

Adult male and female patients with newly diagnosed Philadelphia chromosome positive (Ph+) and/or BCR-ABL1 positive CML can be included in the study until 3 months after diagnosis. A \

Inclusion Criteria: * Male or female patients with diagnosis of CP-CML with cytogenetic confirmation of the Ph+ chromosome \[t(9;22)(q34;q11)\]. * Ph-negative cases or patients with variant translocations who are BCR-ABL1 positive in multiplex PCR 35 will be also considered eligible. * ECOG performance status of ≤2. * Age ≥ 18 years old (no upper age limit is given) * Serum levels of potassium, magnesium, total calcium within the normal limits (≥LLN \[lower limit of normal\] and ≤ULN \[upper limit of normal\]). Correction of electrolytes levels with supplements to fulfil enrolment criteria is allowed. * AST and ALT ≤2.5 x ULN or 5.0 x ULN if considered due to leukemia * Alkaline phosphatase ≤2.5 x ULN unless considered due to leukemia * Total bilirubin ≤1.5 x ULN, except known Gilbert disease * Serum creatinine ≤2 x ULN * Written informed consent prior to any study procedures being performed. Exclusion Criteria: * Allogeneic stem cell transplantation * Known impaired cardiac function, including any of the following: * Congenital long QT syndrome * History of or presence of clinically significant ventricular or atrial tachyarrhythmia * QTc \>450 msec on screening ECG * Myocardial infarction within 12 months prior to starting therapy * Other clinical significant heart disease (e.g. unstable angina, congestive heart failure) * Acute or chronic viral hepatitis with moderate or severe hepatic impairment (Child-Pugh scores \>6), even if controlled * Other concurrent uncontrolled medical conditions (e.g., active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol * Impaired gastrointestinal function or disease that may alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting and diarrhea, malabsorption syndrome, small bowel resection or gastric by-pass surgery) * Concomitant medications known to be strong inducers or inhibitors of the CYP450 isoenzyme CYP3A4 * Patients who have undergone major surgery ≤2 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Patients who are pregnant or breastfeeding or women of reproductive potential not employing an effective method of birth control. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study start. Post-menopausal women must be amenorrheic for at least 12 months in order to be considered of non-childbearing potential. Male and female patients must agree to employ an effective method of birth control throughout the study and for up to 2 weeks following discontinuation of study drug * Known diagnosis of human immunodeficiency virus (HIV) infection (HIV testing is not mandatory) * Known serious hypersensitivity reactions to asciminib, imatinib, nilotinib or dasatinib * Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention * Patients unwilling or unable to comply with the protocol.